Cost–effectiveness analysis in pharmacogenomics

Author： Payne Katherine   Shabaruddin Fatiha H  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.11, Iss.5, 2010-05, pp. : 643-646

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A   Veenstra David   Bebber Stephanie Van   Sakowski Julie  

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics

By Flowers C.R.   Veenstra D.  

PharmacoEconomics, Vol. 22, Iss. 8, 2004-01 ,pp. : 481-493

Adis International

Access to resources Recommend Favorite

On Pharmacogenomics and Cost-Effectiveness Analysis at the Individual Level

By Adis International Limited  

PharmacoEconomics, Vol. 23, Iss. 5, 2005-01 ,pp. : 527-527

Adis International

Access to resources Recommend Favorite

Pharmacogenomics and the Evolution of Healthcare: Is it Time for Cost-Effectiveness Analysis at the Individual Level?

By Bala M.V.  

PharmacoEconomics, Vol. 22, Iss. 8, 2004-01 ,pp. : 495-498

Adis International

Access to resources Recommend Favorite

Does Pharmacogenomics Provide an Ethical Challenge to the Utilisation of Cost-Effectiveness Analysis by Public Health Systems?

By Adam La Caze  

PharmacoEconomics, Vol. 23, Iss. 5, 2005-01 ,pp. : 445-447

Adis International

Access to resources Recommend Favorite